X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare FDC LTD. with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. SUN PHARMA FDC LTD./
SUN PHARMA
 
P/E (TTM) x 17.5 15.3 114.1% View Chart
P/BV x 3.6 3.6 101.2% View Chart
Dividend Yield % 1.3 0.2 610.6%  

Financials

 FDC LTD.   SUN PHARMA
EQUITY SHARE DATA
    FDC LTD.
Mar-14
SUN PHARMA
Mar-16
FDC LTD./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1441,201 12.0%   
Low Rs79706 11.2%   
Sales per share (Unadj.) Rs47.6117.5 40.5%  
Earnings per share (Unadj.) Rs7.619.6 38.8%  
Cash flow per share (Unadj.) Rs9.023.8 37.8%  
Dividends per share (Unadj.) Rs2.251.00 225.0%  
Dividend yield (eoy) %2.00.1 1,928.5%  
Book value per share (Unadj.) Rs47.5130.5 36.4%  
Shares outstanding (eoy) m177.832,406.60 7.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.38.1 28.8%   
Avg P/E ratio x14.648.7 30.0%  
P/CF ratio (eoy) x12.340.1 30.8%  
Price / Book Value ratio x2.37.3 32.0%  
Dividend payout %29.65.1 579.4%   
Avg Mkt Cap Rs m19,7842,294,813 0.9%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m1,22147,971 2.5%   
Avg. sales/employee Rs ThNM19,169.8-  
Avg. wages/employee Rs ThNM3,253.0-  
Avg. net profit/employee Rs ThNM3,197.9-  
INCOME DATA
Net Sales Rs m8,459282,697 3.0%  
Other income Rs m3946,170 6.4%   
Total revenues Rs m8,852288,867 3.1%   
Gross profit Rs m2,07083,239 2.5%  
Depreciation Rs m24910,135 2.5%   
Interest Rs m314,769 0.7%   
Profit before tax Rs m2,18474,505 2.9%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m-225-19 1,202.7%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m6069,349 6.5%   
Profit after tax Rs m1,35347,159 2.9%  
Gross profit margin %24.529.4 83.1%  
Effective tax rate %27.712.5 221.0%   
Net profit margin %16.016.7 95.9%  
BALANCE SHEET DATA
Current assets Rs m4,355308,646 1.4%   
Current liabilities Rs m1,792132,477 1.4%   
Net working cap to sales %30.362.3 48.6%  
Current ratio x2.42.3 104.3%  
Inventory Days Days4483 53.6%  
Debtors Days Days2588 28.1%  
Net fixed assets Rs m3,025133,606 2.3%   
Share capital Rs m1792,407 7.4%   
"Free" reserves Rs m8,243266,909 3.1%   
Net worth Rs m8,453314,042 2.7%   
Long term debt Rs m1131,167 0.0%   
Total assets Rs m10,557542,196 1.9%  
Interest coverage x71.416.6 429.6%   
Debt to equity ratio x00.1 1.3%  
Sales to assets ratio x0.80.5 153.7%   
Return on assets %13.19.6 136.9%  
Return on equity %16.015.0 106.6%  
Return on capital %23.517.8 132.4%  
Exports to sales %13.314.0 95.1%   
Imports to sales %3.33.1 106.4%   
Exports (fob) Rs m1,12639,572 2.8%   
Imports (cif) Rs m2838,882 3.2%   
Fx inflow Rs m1,14642,171 2.7%   
Fx outflow Rs m35521,583 1.6%   
Net fx Rs m79120,588 3.8%   
CASH FLOW
From Operations Rs m1,48567,694 2.2%  
From Investments Rs m-620-44,549 1.4%  
From Financial Activity Rs m-753-19,243 3.9%  
Net Cashflow Rs m1133,902 2.9%  

Share Holding

Indian Promoters % 68.9 63.7 108.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 5.1 91.6%  
FIIs % 7.5 23.0 32.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 8.3 228.9%  
Shareholders   23,730 133,026 17.8%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare FDC LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Aug 18, 2017 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FDC LTD. - GSK PHARMA COMPARISON

COMPARE FDC LTD. WITH

MARKET STATS